Close Menu

NEW YORK (GenomeWeb) – Tataa Biocenter today announced it has signed an exclusive agreement to license the French Institute for Health and Medical Research's (INSERM) ValidPrime qPCR assay correction technology.

ValidPrime is a tool used to measure and compensate for the genomic DNA background signal in qPCR-based gene expression measurements. The technology "accurately corrects all reactions in high-throughput qPCR BioMark arrays for signals derived from gDNA," Vlasta Korenkova, head of Tataa's Prague facility, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.